The CAR-T Therapy Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Factors Such As Increase in Funding From Venture Capitalist And Government Institutes And Increase In Global Burden of Cancer Benefits Are Driving the Market Growth
Some of the major forces propelling the CAR-T Therapy market include increase in funding from venture capitalist and government institutes and increase in global burden of cancer benefits. As per the data published by the WHO, cancer is a leading cause of death globally and caused almost 10 million deaths in 2020.
Based on current and projected population aging and growth, the American Cancer Society, Inc., predicts that the burden of cancer will increase to an estimated 29.4 million cases globally by 2040. China, with the largest population size worldwide has the highest global proportion of cancer new cases and deaths followed by Northern America in terms of new cases and fourth by cancer deaths. Increase in consumption of tobacco & alcohol, unhealthy diet, physical inactivity, and air pollution in various countries across the globe might further increase the cancer burden in future. In the past five years around US$12 billion have been invested by venture capital (VC) firms around the globe, an additional of US$2.2 billion of funding is raised through strategic partnerships between various institutes and biopharma companies.
Reimbursement Challenges and Side-effects of CAR-T Therapy
Reimbursement of CAR-T cell therapies has been a challenge to the healthcare providers, insurers and national & regional government agencies worldwide. CAR-T cell is amongst the most expensive drugs on the market with a price tag of around US$450,000 to US$500,000 per patient. Moreover, patient opting for CAR-T cell often have aggressive deceases resulting in rapid deterioration of health and thus any delays in payer approval can affect patient eligibility for CAR-T cell. Like every other cancer treatment, CAR-T cell therapy also poses severe side effects. Some of the most common occurring side effects are the cytokine release syndrome (CRS) and neurological effects.
What Questions Should You Ask before Buying a Market Research Report?
• How is the CAR-T Therapy market evolving?
• What is driving and restraining the CAR-T Therapy market?
• How will each CAR-T Therapy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each CAR-T Therapy submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading CAR-T Therapy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the CAR-T Therapy projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of CAR-T Therapy projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the CAR-T Therapy market?
• Where is the CAR-T Therapy market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the CAR-T Therapy market today, and over the next 10 years:
• Our 251-page report provides 99 tables and 149 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the CAR-T Therapy market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising CAR-T Therapy prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Indication
• Diffuse Large B-Cell Lymphoma (DLBCL)
• Acute Lymphoblastic Leukemia (ALL)
• Follicular Lymphoma
• Multiple Myeloma (MM)
• Others
Type
• Abecma
• Yescarta
• Kymriah
• Tecartus
• Other
Target Antigens
• CD19/CD22
• BCMA (B-cell maturation antigen)
• Others
Patient
• Children
• Adults
• Seniors
End User
• Hospitals
• Specialty Clinics
• Other End User
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 10 leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
MEA
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the CAR-T Therapy Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• AbbVie Inc.
• Amgen Inc.
• BioNTech SE
• bluebird bio, Inc.
• Bristol-Myers Squibb Company
• Caribou Biosciences Inc.
• Gilead Sciences Inc.
• GSK plc
• Johnson & Johnson Private Limited
• Novartis AG
Overall world revenue for CAR-T Therapy Market, 2022 to 2032 in terms of value the market will surpass US$2.8 billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the CAR-T Therapy Market, 2022 to 2032 report help you?
In summary, our 250+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for CAR-T Therapy Market, 2022 to 2032 Market, with forecasts for indication, type, target antigens, patient, and end-users, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2032 for five regional and 12 key national markets – See forecasts for the CAR-T Therapy Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Germany, France, UK, Italy, Netherlands, China, India, Japan, South Korea, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 10 of the major companies involved in the CAR-T Therapy Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the CAR-T Therapy Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today CAR-T Therapy Market Report 2022-2032: Forecasts by Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukaemia (ALL), Follicular Lymphoma, Multiple Myeloma (MM), Other), by Type (Abecma, Yescarta, Kymriah, Tecartus, Others), by Target Antigens (CD19/CD22, BCMA, Others), by Patient (Children, Adults, Seniors), by End-user (Hospitals, Specialty Clinics, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to CAR-T Therapy Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Global Burden of Cancer Boosting Demand for CAR T Cell
3.2.1.2 Increase in Funding from Venture Capitalist and Government Institutes
3.2.1.3 Expanding Clinical Research Infrastructure in China
3.2.2 Market Restraining Factors
3.2.2.1 Complex Manufacturing and Supply Chain
3.2.2.2 Reimbursement Challenges for CAR-T cell
3.2.2.3 Side Effects of CAR-T cell Therapy
3.2.3 Market Opportunities
3.2.3.1 Growing Use of AI in CAR-T Cell Manufacturing
3.2.3.2 Engineering Controllable CAR-T Cells
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Threat of New Entrants
3.4.4 Threat of Substitutes
3.4.5 Competitive Rivalry
3.5 PEST Analysis
3.5.1 Political
3.5.2 Economic
3.5.3 Social
3.5.4 Technological
4 Car-T Therapy Market Analysis By Indication
4.1 Key Findings
4.2 Indication Segment: Market Attractiveness Index
4.3 Car-T Therapy Market Size Estimation and Forecast by Indication
4.4 Diffuse Large B-Cell Lymphoma (DLBCL)
4.4.1 Market Size by Region, 2022-2032 (US$ bn)
4.4.2 Market Share by Region, 2022 & 2032 (%)
4.5 Acute Lymphoblastic Leukaemia (ALL)
4.5.1 Market Size by Region, 2022-2032 (US$ bn)
4.5.2 Market Share by Region, 2022 & 2032 (%)
4.6 Follicular Lymphoma
4.6.1 Market Size by Region, 2022-2032 (US$ bn)
4.6.2 Market Share by Region, 2022 & 2032 (%)
4.7 Multiple Myeloma (MM)
4.7.1 Market Size by Region, 2022-2032 (US$ bn)
4.7.2 Market Share by Region, 2022 & 2032 (%)
4.8 Others
4.8.1 Market Size by Region, 2022-2032 (US$ bn)
4.8.2 Market Share by Region, 2022 & 2032 (%)
5 Car-T Therapy Market Analysis By Type
5.1 Key Findings
5.2 Type Segment: Market Attractiveness Index
5.3 Car-T Therapy Market Size Estimation and Forecast By Type
5.4 Abecma
5.4.1 Abecma Market Size, 2022-2032 (US$ bn)
5.5 Yescarta
5.5.1 Yescarta Market Size, 2022-2032 (US$ bn)
5.6 Kymriah
5.6.1 Kymriah Market Size, 2022-2032 (US$ bn)
5.7 Tecartus
5.7.1 Tecartus Market Size, 2022-2032 (US$ bn)
5.8 Others
5.8.1 Others Market Size, 2022-2032 (US$ bn)
6 Car-T Therapy Market Analysis By Target Antigens
6.1 Key Findings
6.2 Target Antigens Segment: Market Attractiveness Index
6.3 Car-T Therapy Market Size Estimation and Forecast By Target Antigens
6.4 CD19/CD22
6.4.1 Market Size by Region, 2022-2032 (US$ bn)
6.4.2 Market Share by Region, 2022 & 2032 (%)
6.5 BCMA (B-cell maturation antigen)
6.5.1 Market Size by Region, 2022-2032 (US$ bn)
6.5.2 Market Share by Region, 2022 & 2032 (%)
6.6 Others
6.6.1 Market Size by Region, 2022-2032 (US$ bn)
6.6.2 Market Share by Region, 2022 & 2032 (%)
7 Car-T Therapy Market Analysis By Patient
7.1 Key Findings
7.2 Patient Segment: Market Attractiveness Index
7.3 Car-T Therapy Market Size Estimation and Forecast By Patient
7.4 Children
7.4.1 Market Size by Region, 2022-2032 (US$ bn)
7.4.2 Market Share by Region, 2022 & 2032 (%)
7.5 Adults
7.5.1 Market Size by Region, 2022-2032 (US$ bn)
7.5.2 Market Share by Region, 2022 & 2032 (%)
7.6 Seniors
7.6.1 Market Size by Region, 2022-2032 (US$ bn)
7.6.2 Market Share by Region, 2022 & 2032 (%)
8 Car-T Therapy Market Analysis By End-users
8.1 Key Findings
8.2 End User Segment: Market Attractiveness Index
8.3 Car-T Therapy Market Size Estimation and Forecast By End-users
8.4 Hospitals
8.4.1 Market Size by Region, 2022-2032 (US$ bn)
8.4.2 Market Share by Region, 2022 & 2032 (%)
8.5 Specialty Clinics
8.5.1 Market Size by Region, 2022-2032 (US$ bn)
8.5.2 Market Share by Region, 2022 & 2032 (%)
8.6 Other End-user
8.6.1 Market Size by Region, 2022-2032 (US$ bn)
8.6.2 Market Share by Region, 2022 & 2032 (%)
9 Car-T Therapy Market Analysis by Region
9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast
10 North America Car-T Therapy Market Analysis
10.1 Key Findings
10.2 North America Car-T Therapy Market Attractiveness Index
10.3 North America Car-T Therapy Market by Country, 2022, 2027 & 2032 (US$ bn)
10.4 North America Car-T Therapy Market Size Estimation and Forecast by Country
10.5 North America Car-T Therapy Market Size Estimation and Forecast by Indication
10.6 North America Car-T Therapy Market Size Estimation and Forecast by Target Antigens
10.7 North America Car-T Therapy Market Size Estimation and Forecast by Patients
10.8 North America Car-T Therapy Market Size Estimation and Forecast by End Users
10.9 U.S. Car-T Therapy Market Analysis
10.10 Canada Car-T Therapy Market Analysis
11 Europe Car-T Therapy Market Analysis
11.1 Key Findings
11.2 Europe Car-T Therapy Market Attractiveness Index
11.3 Europe Car-T Therapy Market by Country, 2022, 2027 & 2032 (US$ bn)
11.4 Europe Car-T Therapy Market Size Estimation and Forecast by Country
11.5 Europe Car-T Therapy Market Size Estimation and Forecast By Indication
11.6 Europe Car-T Therapy Market Size Estimation and Forecast by Target Antigens
11.7 Europe Car-T Therapy Market Size Estimation and Forecast by Patients
11.8 Europe Car-T Therapy Market Size Estimation and Forecast by End-users
11.9 Germany Car-T Therapy Market Analysis
11.10 UK Car-T Therapy Market Analysis
11.11 France Car-T Therapy Market Analysis
11.12 Italy Car-T Therapy Market Analysis
11.13 Spain Car-T Therapy Market Analysis
11.14 Netherlands Car-T Therapy Market Analysis
11.15 Rest of Europe Car-T Therapy Market Analysis
12 Asia Pacific Car-T Therapy Market Analysis
12.1 Key Findings
12.2 Asia Pacific Car-T Therapy Market Attractiveness Index
12.3 Asia Pacific Car-T Therapy Market by Country, 2022, 2027 & 2032 (US$ bn)
12.4 Asia Pacific Car-T Therapy Market Size Estimation and Forecast by Country
12.5 Asia Pacific Car-T Therapy Market Size Estimation and Forecast By Indication
12.6 Asia Pacific Car-T Therapy Market Size Estimation and Forecast by Target Antigens
12.7 Asia Pacific Car-T Therapy Market Size Estimation and Forecast by Patients
12.8 Asia Pacific Car-T Therapy Market Size Estimation and Forecast by End-users
12.9 Japan Car-T Therapy Market Analysis
12.10 China Car-T Therapy Market Analysis
12.11 India Car-T Therapy Market Analysis
12.12 Australia Car-T Therapy Market Analysis
12.13 South Korea Car-T Therapy Market Analysis
12.14 Rest of Asia Pacific Car-T Therapy Market Analysis
13 Latin America Car-T Therapy Market Analysis
13.1 Key Findings
13.2 Latin America Car-T Therapy Market Size Estimation and Forecast By Indication
13.3 Latin America Car-T Therapy Market Size Estimation and Forecast by Target Antigens
13.4 Latin America Car-T Therapy Market Size Estimation and Forecast by Patients
13.5 Latin America Car-T Therapy Market Size Estimation and Forecast by End-users
13.6 Brazil Car-T Therapy Market Analysis
13.7 Mexico Car-T Therapy Market Analysis
13.8 Rest of Latin America Car-T Therapy Market Analysis
14 MEA Car-T Therapy Market Analysis
14.1 Key Findings
14.2 MEA Car-T Therapy Market Size Estimation and Forecast By Indication
14.3 MEA Car-T Therapy Market Size Estimation and Forecast by Target Antigens
14.4 MEA Car-T Therapy Market Size Estimation and Forecast by Patient
14.5 MEA Car-T Therapy Market Size Estimation and Forecast by End-users
14.6 GCC Car-T Therapy Market Analysis
14.7 Rest of Middle East and Africa Car-T Therapy Market Analysis
15 Company Profiles
15.1 Competitive Landscape, 2021
15.2 Strategic Outlook
15.3 Novartis AG
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2017-2021
15.3.3.2 R&D, 2017-2021
15.3.3.3 Regional Market Shares, 2021
15.3.4 Product Benchmarking
15.3.5 Strategic Outlook
15.4 Gilead Sciences, Inc.
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.3.1 Net Revenue, 2017-2021
15.4.3.2 R&D, 2017-2021
15.4.3.3 Regional Market Shares, 2021
15.4.4 Product Benchmarking
15.4.5 Strategic Outlook
15.5 Bristol-Myers Squibb Company
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2017-2021
15.5.3.2 R&D, 2017-2021
15.5.3.3 Regional Market Shares, 2021
15.5.4 Product Benchmarking
15.5.5 Strategic Outlook
15.6 Johnson & Johnson Private Limited
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.3.1 Net Revenue, 2017-2021
15.6.3.2 R&D, 2017-2021
15.6.3.3 Regional Market Shares, 2021
15.6.4 Product Benchmarking
15.6.5 Strategic Outlook
15.7 bluebird bio, Inc.
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2017-2021
15.7.3.2 R&D, 2017-2021
15.7.4 Product Benchmarking
15.7.5 Strategic Outlook
15.8 GSK plc
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Financial Analysis
15.8.3.1 Net Revenue, 2017-2021
15.8.3.2 R&D, 2017-2021
15.8.3.3 Regional Market Shares, 2021
15.8.4 Product Benchmarking
15.8.5 Strategic Outlook
15.9 Caribou Biosciences Inc
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Financial Analysis
15.9.3.1 Net Revenue, 2019-2021
15.9.3.2 R&D, 2019-2021
15.9.3.3 Regional Market Shares, 2021
15.9.4 Product Benchmarking
15.9.5 Strategic Outlook
15.10 Amgen Inc.
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.3.1 Net Revenue, 2017-2021
15.10.3.2 R&D, 2017-2021
15.10.3.3 Regional Market Shares, 2021
15.10.4 Product Benchmarking
15.10.5 Strategic Outlook
15.11 AbbVie Inc.
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Financial Analysis
15.11.3.1 Net Revenue, 2017-2021
15.11.3.2 R&D, 2017-2021
15.11.3.3 Regional Market Shares, 2021
15.11.4 Product Benchmarking
15.11.5 Strategic Outlook
15.12 BioNTech SE
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Financial Analysis
15.12.3.1 Net Revenue, 2017-2021
15.12.3.2 R&D, 2017-2021
15.12.4 Product Benchmarking
15.12.5 Strategic Outlook
16 Conclusion and Recommendations
16.1 Concluding Remarks from Visiongain
16.2 Recommendations for Market Players
List of Tables
Table 1 CAR-T Therapy Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Car-T Therapy Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%)): “V” Shaped Recovery Scenario
Table 3 Car-T Therapy Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%)): “U” Shaped Recovery Scenario
Table 4 Car-T Therapy Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%)): “W” Shaped Recovery Scenario
Table 5 Car-T Therapy Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%)): “L” Shaped Recovery Scenario
Table 6 Car-T Therapy Market Forecast By Indication, 2022-2032 (US$ Bn, AGR%, CAGR%)
Table 7 DLBCL Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 8 ALL Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 9 Follicular Lymphoma Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 10 Multiple Myeloma (MM) Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 11 Others Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 12 Car-T Therapy Market Forecast By Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 13 Abecma Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 14 Yescarta Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 15 Kymriah Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 16 Tecartus Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 17 Others Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 18 Car-T Therapy Market Forecast By Target Antigens, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 19 CD19/CD22 Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 20 BCMA Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 21 Others Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 22 Car-T Therapy Market Forecast By Patient, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 23 Children Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 24 Adults Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 25 Seniors Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 26 Car-T Therapy Market Forecast By End-users, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 27 Hospitals Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 28 Specialty Clinics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 29 Other End-user Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 30 Car-T Therapy Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR(%))
Table 31 North America Car-T Therapy Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 32 North America Car-T Therapy Market Forecast By Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 33 North America Car-T Therapy Market Forecast by Target Antigens, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 34 North America Car-T Therapy Market Forecast by Patients, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 35 North America Car-T Therapy Market Forecast by End Users, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 36 U.S. Car-T Therapy Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 37 Canada Car-T Therapy Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 38 Europe Car-T Therapy Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 39 Europe Car-T Therapy Market Forecast By Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 40 Europe Car-T Therapy Market Forecast by Target Antigens, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 41 Europe Car-T Therapy Market Forecast by Patients, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 42 Europe Car-T Therapy Market Forecast by End-users, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 43 Germany Car-T Therapy Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 44 UK Car-T Therapy Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 45 France Car-T Therapy Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 46 Italy Car-T Therapy Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 47 Spain Car-T Therapy Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 48 Netherlands Car-T Therapy Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 49 Rest of Europe Car-T Therapy Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 50 Asia Pacific Car-T Therapy Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 51 Asia Pacific Car-T Therapy Market Forecast By Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 52 Asia Pacific Car-T Therapy Market Forecast by Target Antigens, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 53 Asia Pacific Car-T Therapy Market Forecast by Patients, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 54 Asia Pacific Car-T Therapy Market Forecast by End-users, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 55 Japan Car-T Therapy Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 56 China Car-T Therapy Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 57 India Car-T Therapy Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 58 Australia Car-T Therapy Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 59 South Korea Car-T Therapy Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 60 Rest of Asia Pacific Car-T Therapy Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 61 Latin America Car-T Therapy Market Forecast By Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 62 Latin America Car-T Therapy Market Forecast by Target Antigens, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 63 Latin America Car-T Therapy Market Forecast by Patients, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 64 Latin America Car-T Therapy Market Forecast by End-users, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 65 MEA Car-T Therapy Market Forecast By Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 66 MEA Car-T Therapy Market Forecast by Target Antigens, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 67 MEA Car-T Therapy Market Forecast by Patient, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 68 MEA Car-T Therapy Market Forecast by End-users, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 69 Strategic Outlook
Table 70 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 71 Novartis AG: Product Benchmarking
Table 72 Novartis AG: Strategic Outlook
Table 73 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 74 Gilead Science, Inc.: Product Benchmarking
Table 75 Gilead Science, Inc.: Strategic Outlook
Table 76 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 77 Bristol-Myers Squibb Company: Product Benchmarking
Table 78 Bristol-Myers Squibb Company: Strategic Outlook
Table 79 Johnson & Johnson Private Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 80 Johnson & Johnson Private Limited: Product Benchmarking
Table 81 Johnson & Johnson Private Limited: Strategic Outlook
Table 82 bluebird bio, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 83 bluebird bio, Inc.: Product Benchmarking
Table 84 bluebird bio, Inc.: Strategic Outlook
Table 85 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 GSK plc: Product Benchmarking
Table 87 GSK plc: Strategic Outlook
Table 88 Caribou Biosciences Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 Caribou Biosciences Inc: Product Benchmarking
Table 90 Caribou Biosciences Inc: Strategic Outlook
Table 91 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 92 Amgen Inc.: Product Benchmarking
Table 93 Amgen Inc.: Strategic Outlook
Table 94 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 AbbVie Inc.: Product Benchmarking
Table 96 AbbVie Inc.: Strategic Outlook
Table 97 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 BioNTech SE: Product Benchmarking
Table 99 BioNTech SE: Strategic Outlook
List of Figures
Figure 1 CAR-T Therapy Market Segmentation
Figure 2 CAR-T Therapy Market by Region: Market Attractiveness Index
Figure 3 CAR-T Therapy Market By Indication: Market Attractiveness Index
Figure 4 CAR-T Therapy Market: Market Dynamics
Figure 5 COVID Impact Analysis: Car-T Therapy Market Recovery Scenarios
Figure 6 Car-T Therapy Market by Region, 2022-2032 (US$ bn, AGR %): “V” Shaped Recovery
Figure 7 Car-T Therapy Market by Region, 2022-2032 (US$ bn, AGR %): “U” Shaped Recovery
Figure 8 Car-T Therapy Market by Region, 2022-2032 (US$ bn, AGR %): “W” Shaped Recovery
Figure 9 Car-T Therapy Market by Region, 2022-2032 (US$ bn, AGR %): “L” Shaped Recovery
Figure 10 CAR-T Therapy Market: Porter’s Five Forces Analysis
Figure 11 Bargaining Power of Suppliers
Figure 12 Bargaining Power of Buyers
Figure 13 Threat of New Entrants
Figure 14 Threat of Substitutes
Figure 15 Competitive Rivalry
Figure 16 CART Therapy Market: PEST Analysis
Figure 17 Car-T Therapy Market Forecast By Indication 2022, 2027, 2032 (Revenue, CAGR%)
Figure 18 Car-T Therapy Market Forecast By Indication, 2022-2032 (US$ billion)
Figure 19 Car-T Therapy Market Share Forecast By Indication, 2022, 2027, 2032 (%)
Figure 20 DLBCL Market Forecast by Region, 2022-2032 (US$ billion)
Figure 21 DLBCL Market Share Forecast by Region, 2022 & 2032 (%)
Figure 22 ALL Market Forecast by Region, 2022-2032 (US$ billion)
Figure 23 ALL Market Share Forecast by Region, 2022 & 2032 (%)
Figure 24 Follicular Lymphoma Market Forecast by Region, 2022-2032 (US$ billion)
Figure 25 Follicular Lymphoma Market Share Forecast by Region, 2022 & 2032 (%)
Figure 26 Multiple Myeloma (MM) Market Forecast by Region, 2022-2032 (US$ billion)
Figure 27 Multiple Myeloma (MM) Market Share Forecast by Region, 2022 & 2032 (%)
Figure 28 Others Market Forecast by Region, 2022-2032 (US$ billion)
Figure 29 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 30 Car-T Therapy Market Attractiveness Index by Type
Figure 31 Car-T Therapy Market Forecast By Type, 2022-2032 (US$ billion)
Figure 32 Car-T Therapy Market Share Forecast By Type, 2022, 2027, 2032 (%)
Figure 33 Abecma Market Forecast, 2022-2032 (US$ billion)
Figure 34 Yescarta Market Forecast, 2022-2032 (US$ billion)
Figure 35 Kymriah Market Forecast, 2022-2032 (US$ billion)
Figure 36 Tecartus Market Forecast, 2022-2032 (US$ billion)
Figure 37 Others Market Forecast, 2022-2032 (US$ billion)
Figure 38 Car-T Therapy Market Attractiveness Index by Target Antigens
Figure 39 Car-T Therapy Market Forecast By Target Antigens, 2022-2032 (US$ billion)
Figure 40 Car-T Therapy Market Share Forecast By Target Antigens, 2022, 2027, 2032 (%)
Figure 41 CD19/CD22 Market Forecast by Region, 2022-2032 (US$ billion)
Figure 42 CD19/CD22 Market Share Forecast by Region, 2022 & 2032 (%)
Figure 43 BCMA Market Forecast by Region, 2022-2032 (US$ billion)
Figure 44 BCMA Market Share Forecast by Region, 2022 & 2032 (%)
Figure 45 Others Market Forecast by Region, 2022-2032 (US$ billion)
Figure 46 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 47 Car-T Therapy Market Attractiveness Index by Patient
Figure 48 Car-T Therapy Market Forecast By Patient, 2022-2032 (US$ billion)
Figure 49 Car-T Therapy Market Share Forecast By Patient, 2022, 2027, 2032 (%)
Figure 50 Children Market Forecast by Region, 2022-2032 (US$ billion)
Figure 51 Children Market Share Forecast by Region, 2022 & 2032 (%)
Figure 52 Adults Market Forecast by Region, 2022-2032 (US$ billion)
Figure 53 Adults Market Share Forecast by Region, 2022 & 2032 (%)
Figure 54 Seniors Market Forecast by Region, 2022-2032 (US$ billion)
Figure 55 Seniors Market Share Forecast by Region, 2022 & 2032 (%)
Figure 56 Car-T Therapy Market Attractiveness Index by End-users
Figure 57 Car-T Therapy Market Forecast By End-users, 2022-2032 (US$ billion)
Figure 58 Car-T Therapy Market Share Forecast By End-users, 2022, 2027, 2032 (%)
Figure 59 Hospitals Market Forecast by Region, 2022-2032 (US$ billion)
Figure 60 Hospitals Market Share Forecast by Region, 2022 & 2032 (%)
Figure 61 Specialty Clinics Market Forecast by Region, 2022-2032 (US$ billion)
Figure 62 Specialty Clinics Market Share Forecast by Region, 2022 & 2032 (%)
Figure 63 Other End-user Market Forecast by Region, 2022-2032 (US$ billion)
Figure 64 Other End-user Market Share Forecast by Region, 2022 & 2032 (%)
Figure 65 Car-T Therapy Market Forecast by Region 2022 - 2032 (Revenue, CAGR%)
Figure 66 Car-T Therapy Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 67 Car-T Therapy Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%))
Figure 68 North America Car-T Therapy Market Attractiveness Index
Figure 69 North America Car-T Therapy Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 70 North America Car-T Therapy Market Forecast by Country, 2022-2032 (US$ billion)
Figure 71 North America Car-T Therapy Market Share Forecast by Country, 2022 & 2032 (%)
Figure 72 North America Car-T Therapy Market Forecast By Indication, 2022-2032 (US$ billion)
Figure 73 North America Car-T Therapy Market Share Forecast By Indication, 2022 & 2032 (%)
Figure 74 North America Car-T Therapy Market Forecast by Target Antigens, 2022-2032 (US$ million)
Figure 75 North America Car-T Therapy Market Share Forecast by Target Antigens, 2022 & 2032 (%)
Figure 76 North America Car-T Therapy Market Forecast by Patients, 2022-2032 (US$ billion)
Figure 77 North America Car-T Therapy Market Share Forecast by Patients, 2022 & 2032 (%)
Figure 78 North America Car-T Therapy Market Forecast by End Users, 2022-2032 (US$ billion)
Figure 79 North America Car-T Therapy Market Share Forecast by End Users, 2022 & 2032 (%)
Figure 80 U.S. Car-T Therapy Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 81 Canada Car-T Therapy Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 82 Europe Car-T Therapy Market Attractiveness Index
Figure 83 Europe Car-T Therapy Market by Country, 2022, 2027 & 2032 (US$ billion)
Figure 84 Europe Car-T Therapy Market Forecast by Country, 2022-2032 (US$ billion)
Figure 85 Europe Car-T Therapy Market Share Forecast by Country, 2022 & 2032 (%)
Figure 86 Europe Car-T Therapy Market Forecast By Indication, 2022-2032 (US$ billion)
Figure 87 Europe Car-T Therapy Market Share Forecast By Indication, 2022 & 2032 (%)
Figure 88 Europe Car-T Therapy Market Forecast by Target Antigens, 2022-2032 (US$ billion)
Figure 89 Europe Car-T Therapy Market Share Forecast by Target Antigens, 2022 & 2032 (%)
Figure 90 Europe Car-T Therapy Market Forecast by Patients, 2022-2032 (US$ billion)
Figure 91 Europe Car-T Therapy Market Share Forecast by Patients, 2022 & 2032 (%)
Figure 92 Europe Car-T Therapy Market Forecast by End-users, 2022-2032 (US$ billion)
Figure 93 Europe Car-T Therapy Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 94 Germany Car-T Therapy Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 95 UK Car-T Therapy Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 96 France Car-T Therapy Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 97 Italy Car-T Therapy Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 98 Spain Car-T Therapy Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 99 Netherlands Car-T Therapy Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 100 Rest of Europe Car-T Therapy Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 101 Asia Pacific Car-T Therapy Market Attractiveness Index
Figure 102 Asia Pacific Car-T Therapy Market by Country, 2022, 2027 & 2032 (US$ billion)
Figure 103 Asia Pacific Car-T Therapy Market Forecast by Country, 2022-2032 (US$ billion)
Figure 104 Asia Pacific Car-T Therapy Market Share Forecast by Country, 2022 & 2032 (%)
Figure 105 Asia Pacific Car-T Therapy Market Forecast By Indication, 2022-2032 (US$ billion)
Figure 106 Asia Pacific Car-T Therapy Market Share Forecast By Indication, 2022 & 2032 (%)
Figure 107 Asia Pacific Car-T Therapy Market Forecast by Target Antigens, 2022-2032 (US$ billion)
Figure 108 Asia Pacific Car-T Therapy Market Share Forecast by Target Antigens, 2022 & 2032 (%)
Figure 109 Asia Pacific Car-T Therapy Market Forecast by Patients, 2022-2032 (US$ billion)
Figure 110 Asia Pacific Car-T Therapy Market Share Forecast by Patients, 2022 & 2032 (%)
Figure 111 Asia Pacific Car-T Therapy Market Forecast by End-users, 2022-2032 (US$ billion)
Figure 112 Asia Pacific Car-T Therapy Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 113 Japan Car-T Therapy Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 114 China Car-T Therapy Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 115 India Car-T Therapy Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 116 Australia Car-T Therapy Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 117 South Korea Car-T Therapy Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 118 Rest of Asia Pacific Car-T Therapy Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 119 Latin America Car-T Therapy Market Forecast By Indication, 2022-2032 (US$ billion)
Figure 120 Latin America Car-T Therapy Market Share Forecast By Indication, 2022 & 2032 (%)
Figure 121 Latin America Car-T Therapy Market Forecast by Target Antigens, 2022-2032 (US$ billion)
Figure 122 Latin America Car-T Therapy Market Share Forecast by Target Antigens, 2022 & 2032 (%)
Figure 123 Latin America Car-T Therapy Market Forecast by Patients, 2022-2032 (US$ billion)
Figure 124 Latin America Car-T Therapy Market Share Forecast by Patients, 2022 & 2032 (%)
Figure 125 Latin America Car-T Therapy Market Forecast by End-users, 2022-2032 (US$ billion)
Figure 126 Latin America Car-T Therapy Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 127 MEA Car-T Therapy Market Forecast By Indication, 2022-2032 (US$ billion)
Figure 128 MEA Car-T Therapy Market Share Forecast By Indication, 2022 & 2032 (%)
Figure 129 MEA Car-T Therapy Market Forecast by Target Antigens, 2022-2032 (US$ billion)
Figure 130 MEA Car-T Therapy Market Share Forecast by Target Antigens, 2022 & 2032 (%)
Figure 131 MEA Car-T Therapy Market Forecast by Patient, 2022-2032 (US$ billion)
Figure 132 MEA Car-T Therapy Market Share Forecast by Patient, 2022 & 2032 (%)
Figure 133 MEA Car-T Therapy Market Forecast by End-users, 2022-2032 (US$ billion)
Figure 134 MEA Car-T Therapy Market Share Forecast by End-users, 2022 & 2032 (%)
Figure 135 Car-T Therapy Market: Company Share/Ranking, 2021
Figure 136 Novartis AG: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 137 Novartis AG: R&D, 2017-2021 (US$ million, AGR%)
Figure 138 Novartis AG: Regional Market Shares, 2021
Figure 139 Gilead Science, Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 140 Gilead Science, Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 141 Gilead Science, Inc.: Regional Market Shares, 2021
Figure 142 Bristol-Myers Squibb Company: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 143 Bristol-Myers Squibb Company: R&D, 2017-2021 (US$ million, AGR%)
Figure 144 Bristol-Myers Squibb Company: Regional Market Shares, 2021
Figure 145 Johnson & Johnson Private Limited: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 146 Johnson & Johnson Private Limited: R&D, 2017-2021 (US$ million, AGR%)
Figure 147 Johnson & Johnson Private Limited: Regional Market Shares, 2021
Figure 148 bluebird bio, Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 149 bluebird bio, Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 150 GSK plc: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 151 GSK plc: R&D, 2017-2021 (US$ million, AGR%)
Figure 152 GSK plc: Regional Market Shares, 2021
Figure 153 Caribou Biosciences Inc: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 154 Caribou Biosciences Inc: R&D, 2019-2021 (US$ million, AGR%)
Figure 155 Caribou Biosciences Inc: Regional Market Shares, 2021
Figure 156 Amgen Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 157 Amgen Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 158 Amgen Inc.: Regional Market Shares, 2021
Figure 159 AbbVie Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 160 AbbVie Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 161 AbbVie Inc.: Regional Market Shares, 2021
Figure 162 BioNTech SE: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 163 BioNTech SE: R&D, 2017-2021 (US$ million, AGR%)
List of Companies Profiled in the Report
AbbVie Inc.
Amgen Inc.
BioNTech SE
bluebird bio, Inc.
Bristol-Myers Squibb Company
Caribou Biosciences Inc
Gilead Sciences, Inc.
GSK plc
Johnson & Johnson Private Limited
Novartis AG
List of Other Companies Mentioned in the Report
Adaptimmune
Aleta BioTherapeutics
AlloCAR-T Therapy
Allogene Therapeutics
Anixa Biosciences, Inc.
Arcellx, Inc.
Atara Biotherapeutics
Atela’s Pipeline
Autolus Therapeutics, plc
Bellicum Pharmaceuticals, Inc.
Cabaletta Bio
Carina Biotech
CART-ddBCMA
Cartesian Therapeutics, Inc.
Cellectis S.A.
Celularity Inc.
Celyad Oncology SA
Eli Lilly and Company
Eureka Therapeutics
Fate Therapeutics
Fortress Biotech
Fortress Biotech, Inc
GigaGen
GoCAR Technology
Immune Therapeutics
ImmunoACT
Imugene Ltd
Intellia Therapeutics (US)
Janssen Pharmaceuticals, Inc.
Juno Therapeutics
Legend Biotech Corporation
Merck KGaA
NantKwest
Noile-Immune Biotech (Japan)
Pfizer, Inc.
Servier Laboratories (France)
Sorrento Therapeutics, Inc.
TCR2 Therapeutics Inc
Tessa Therapeutics
TILT Biotherapeutics
TScan Therapeutics
Ziopharm
List of Associations Mentioned in the Report
Abu Dhabi Stem Cells Centre (ADSCC)
Agência Nacional de Vigilância Sanitária (ANVISA)
American Cancer Society, Inc.
APEX National Investment
Autolus Therapeutics
Behemoth Gilead Sciences, Inc.
Beijing Genome Institute
Biomedical Research and Innovation at Kobe
BioOra
Biotechnology Industry Research Assistance Council (BIRAC)
Blackstone Life Sciences
Bridgewest Ventures NZ
Centenary Institute
China National GeneBank Shenzhen
Chris O'Brien Lifehouse
Dana-Farber Cancer Institute
Eight Roads Ventures,
Fosun Pharma Kite Biotechnology
F-Prime Capital
Georgia Institute of Technology
Health Sciences Authority of Singapore
Hospital das Clínicas de Ribeirão Preto (HCRP),
Immuneel Therapeutics Pvt. Ltd.
ImmunoACT
Indian Institute of Technology Bombay
International Agency Tor Research on Cancer (IARC)
Japanese Ministry of Health, Labour and Welfare
Li Ka Shing Foundation
Mass General Cancer Center
Medicare & Medicaid Services (CMS)
Microsoft
Miltenyi Biotec
National Institutes of Health (NIH)
National Medical Products Administration of China
National University Hospital (NUH)
NHMRC Clinical Trials Centre
ORI Capital
Otsuka Pharmaceutical
Royal Prince Alfred Hospital
Samsung Medical Centre
San Diego School of Medicine
School of Medicine of Ribeirão Preto
School of Medicine of São Paulo
Shanghai Fosun Pharmaceutical Group Co. Ltd.
Sheba Medical Center's Pediatric Hemato-Oncology Department
Shenzhen Geno-Immune Medical Institute
Singapore General Hospital (SGH)
Sydney Cancer Research Network
Sydney Catalyst
Tata Memorial Center Mumbai
The Bioscience and Bioengineering (BSBE)
The Department of Biotechnology (DBT)
the European Parliament and the Council of the European Union
The Malaghan Institute
The University of Texas
The US Food and Drug Administration (FDA)
Therapeutic Goods Administration (TGA)
True North
University of California
University of Pennsylvania
university of Sao Paulo in Ribeirao Preto
University of Sydney
Wellington Zhaotai Therapies
World Health Organization (WHO)
WuXi AppTec
Xuzhou Medical University
Zhejiang University
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
